HC Wainwright Issues Negative Estimate for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of CervoMed in a research report issued on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.92) for the quarter, down from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.62) EPS.

Several other equities research analysts have also issued reports on CRVO. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Chardan Capital increased their price objective on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday. Roth Mkm decreased their price objective on CervoMed from $19.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday. raised CervoMed to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Monday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

CervoMed Trading Down 0.2%

Shares of CRVO opened at $4.23 on Thursday. CervoMed has a 12 month low of $3.58 and a 12 month high of $16.94. The firm has a fifty day simple moving average of $5.21 and a 200 day simple moving average of $7.19. The stock has a market capitalization of $39.17 million, a price-to-earnings ratio of -1.42 and a beta of -0.77.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.84 million.

Hedge Funds Weigh In On CervoMed

Large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares during the period. State Street Corp raised its holdings in CervoMed by 11.4% in the 4th quarter. State Street Corp now owns 20,527 shares of the company’s stock valued at $162,000 after acquiring an additional 2,100 shares during the period. Thompson Davis & CO. Inc. raised its holdings in CervoMed by 20.8% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 16,850 shares of the company’s stock valued at $136,000 after acquiring an additional 2,900 shares during the period. Vanguard Group Inc. lifted its position in CervoMed by 1.0% during the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after acquiring an additional 3,445 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its position in CervoMed by 14.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,477 shares of the company’s stock worth $247,000 after acquiring an additional 3,800 shares during the last quarter. 25.15% of the stock is owned by institutional investors.

CervoMed News Roundup

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data presented at the AD/PD 2026 conference show that neflamapimod produced greater benefit in Dementia with Lewy Bodies (DLB) patients who have low plasma pTau181 (i.e., likely without Alzheimer’s co‑pathology). This can increase the perceived commercial and regulatory value of the program for a clearer DLB target population. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy and a $25 price target while trimming some near-term EPS forecasts but raising several quarterly and FY2026/FY2027 estimates overall (and raising some quarter estimates). The firm’s maintained Buy and higher longer‑term estimates support upside expectations. MarketBeat: HC Wainwright Notes
• Positive Sentiment: Chardan Capital raised its price target from $15 to $21 and kept a Buy rating, signaling investor conviction from another boutique healthcare analyst. TickerReport: Chardan Raise
• Positive Sentiment: D. Boral Capital published a Buy rating on CRVO, adding to the list of brokers expressing conviction in the story. American Banking News: Buy Rating
• Neutral Sentiment: Coverage notes and press summaries report the company was “flat” on Q4/FY results; no new material guidance or financing announcements were reported in those summaries. Market reaction may therefore hinge on interpretation of pipeline updates and analyst notes. BayStreet: Flat on Q4/FY
• Neutral Sentiment: Reported short‑interest data for March are effectively meaningless in the published entry (shows 0 shares / NaN change), so short‑squeeze or added short pressure is not an active driver based on that report.
• Negative Sentiment: Roth MKM lowered its price target from $19 to $11 (while still on Buy), which reduces near‑term analyst upside and could pressure sentiment among investors focused on published targets. Benzinga: Roth MKM PT Cut
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (worse near‑term quarterly view), underscoring continued execution and cash‑burn risk until definitive late‑stage data or partnering/financing alleviates funding concerns.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.